Advanced search
Publication Cover
The World Journal of Biological Psychiatry Volume 10, 2009 - Issue 4-2
Submit an article Journal homepage
502
Views
59
CrossRef citations to date
0
Altmetric
Case Reports

Beneficial effects of N-acetylcysteine in treatment resistant schizophrenia

Mahmut Bulut Department of Psychiatry, Gaziantep University Faculty of Medicine, Gaziantep, Turkey
,
Haluk Asuman Savas Department of Psychiatry, Gaziantep University Faculty of Medicine, Gaziantep, TurkeyCorrespondence[email protected]
,
Abdurrahman Altindag Department of Psychiatry, Gaziantep University Faculty of Medicine, Gaziantep, Turkey
,
Osman Virit Department of Psychiatry, Gaziantep University Faculty of Medicine, Gaziantep, Turkey
&
Alican Dalkilic St. Elizabeths Hospital, Washington, DC, USA
Pages 626-628 | Received 11 Jan 2008, Published online: 08 Dec 2009

Citations (59)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Caitlin O. B. Yolland, Andrea Phillipou, David J. Castle, Erica Neill, Matthew E. Hughes, Cherrie Galletly, Zoe M. Smith, Paul S. Francis, Olivia M. Dean, Jerome Sarris, Dan Siskind, Anthony W. F. Harris & Susan L. Rossell. (2020) Improvement of cognitive function in schizophrenia with N-acetylcysteine: A theoretical review. Nutritional Neuroscience 23:2, pages 139-148.
Read now
Alessandro Minarini, Silvia Ferrari, Martina Galletti, Nina Giambalvo, Daniela Perrone, Giulia Rioli & Gian Maria Galeazzi. (2017) N-acetylcysteine in the treatment of psychiatric disorders: current status and future prospects. Expert Opinion on Drug Metabolism & Toxicology 13:3, pages 279-292.
Read now
Mehmet Gunes, Abdurrahman Altindag, Mahmut Bulut, Suleyman Demir, Aslihan Okan Ibiloglu, Mehmet Cemal Kaya, Abdullah Atli & Nurten Aksoy. (2017) Oxidative metabolism may be associated with negative symptoms in schizophrenia. Psychiatry and Clinical Psychopharmacology 27:1, pages 54-61.
Read now
Dhaval Patel, Prashant S. Kharkar & Mukesh Nandave. (2015) Emerging roles of system antiporter and its inhibition in CNS disorders. Molecular Membrane Biology 32:4, pages 89-116.
Read now
Jan Malte Bumb, Frank Enning & F Markus Leweke. (2015) Drug repurposing and emerging adjunctive treatments for schizophrenia. Expert Opinion on Pharmacotherapy 16:7, pages 1049-1067.
Read now

Articles from other publishers (54)

Kıymet Kübra Tüfekci̇, Musa Tatar, Funda Terzi̇ & Elfide Gizem Bakirhan. (2023) An investigation of the endoplasmic reticulum stress in obesity exposure in the prenatal period. Journal of Chemical Neuroanatomy 134, pages 102348.
Crossref
Murat Sırrı Akosman, Ruhi Türkmen & Hasan Hüseyin Demirel. (2023) The protective effect of N-acetylcysteine against MK-801-induced neurodegeneration in mice. Molecular Biology Reports 50:12, pages 10287-10299.
Crossref
Huimin Wei, Huimin Jiang, Yifan Zhou, Xuechun Xiao, Chen Zhou & Xunming Ji. (2023) Cerebral venous congestion alters brain metabolite profiles, impairing cognitive function. Journal of Cerebral Blood Flow & Metabolism 43:11, pages 1857-1872.
Crossref
Alessandro Serretti. (2023) Innovation in psychopharmacology. International Clinical Psychopharmacology 38:5, pages 281-284.
Crossref
Narasimha M. Beeraka, Marco F. Avila-Rodriguez & Gjumrakch Aliev. (2022) Recent Reports on Redox Stress-Induced Mitochondrial DNA Variations, Neuroglial Interactions, and NMDA Receptor System in Pathophysiology of Schizophrenia. Molecular Neurobiology 59:4, pages 2472-2496.
Crossref
David M. Taylor, Thomas R. E. Barnes & Allan H. Young. 2021. The Maudsley Prescribing Guidelines in Psychiatry. The Maudsley Prescribing Guidelines in Psychiatry 1 224 .
Ahmed Naguy & Camellia Naguy. (2020) N-acetyl-cysteine in schizophrenia—there is more than meets the eyes!. CNS Spectrums 26:5, pages 446-447.
Crossref
Alexandrina S. Curpan, Alina-Costina Luca & Alin Ciobica. (2021) Potential Novel Therapies for Neurodevelopmental Diseases Targeting Oxidative Stress. Oxidative Medicine and Cellular Longevity 2021, pages 1-13.
Crossref
Irena Smaga, Małgorzata Frankowska & Małgorzata Filip. (2021) N ‐acetylcysteine as a new prominent approach for treating psychiatric disorders . British Journal of Pharmacology 178:13, pages 2569-2594.
Crossref
Evgeny A. Ermakov, Elena M. Dmitrieva, Daria A. Parshukova, Daria V. Kazantseva, Alisa R. Vasilieva & Liudmila P. Smirnova. (2021) Oxidative Stress-Related Mechanisms in Schizophrenia Pathogenesis and New Treatment Perspectives. Oxidative Medicine and Cellular Longevity 2021, pages 1-37.
Crossref
Zehra Boz, Minmin Hu, Yinghua Yu & Xu-Feng Huang. (2020) N-acetylcysteine prevents olanzapine-induced oxidative stress in mHypoA-59 hypothalamic neurons. Scientific Reports 10:1.
Crossref
Azi̇z Ahmet GÜNDOĞAR & Murat Sirri AKOSMAN. (2020) THE PROTECTIVE EFFECT OF THE RESVERATROL AND N-ACETYLCYSTEINE COMBINATION ON THE LOCOMOTOR HYPERACTIVITY INDUCED WITH MK-801. Kocatepe Veterinary Journal.
Crossref
Kara Dempster, Peter Jeon, Michael MacKinley, Peter Williamson, Jean Théberge & Lena Palaniyappan. (2020) Early treatment response in first episode psychosis: a 7-T magnetic resonance spectroscopic study of glutathione and glutamate. Molecular Psychiatry 25:8, pages 1640-1650.
Crossref
Naista Zhand, David G. Attwood & Philip D. Harvey. (2019) Glutamate modulators for treatment of schizophrenia. Personalized Medicine in Psychiatry 15-16, pages 1-12.
Crossref
A. Maia, J. Oliveira, M. Lajnef, L. Mallet, R. Tamouza, M. Leboyer & A. J. Oliveira‐Maia. (2019) Oxidative and nitrosative stress markers in obsessive–compulsive disorder: a systematic review and meta‐analysis. Acta Psychiatrica Scandinavica 139:5, pages 420-433.
Crossref
Amir Ghaderi, Anna Bussu, Catherine Tsang & Sadegh Jafarnejad. (2018) RETRACTED ARTICLE: Effect of N-acetyl cysteine (NAC) supplementation on positive and negative syndrome scale in schizophrenia: a systematic review and meta-analysis of randomised controlled trials. European Journal of Clinical Pharmacology 75:3, pages 289-301.
Crossref
John Slattery & Richard Eugene Frye. 2019. The Therapeutic Use of N-Acetylcysteine (NAC) in Medicine. The Therapeutic Use of N-Acetylcysteine (NAC) in Medicine 203 218 .
Grant McQueen, John Lally, Tracy Collier, Fernando Zelaya, David J. Lythgoe, Gareth J. Barker, James M. Stone, Philip McGuire, James H. MacCabe & Alice Egerton. (2018) Effects of N-acetylcysteine on brain glutamate levels and resting perfusion in schizophrenia. Psychopharmacology 235:10, pages 3045-3054.
Crossref
W. Zheng, Q.-E. Zhang, D.-B. Cai, X.-H. Yang, Y. Qiu, G. S. Ungvari, C. H. Ng, M. Berk, Y.-P. Ning & Y.-T. Xiang. (2018) N -acetylcysteine for major mental disorders: a systematic review and meta-analysis of randomized controlled trials . Acta Psychiatrica Scandinavica 137:5, pages 391-400.
Crossref
Lin Zhang, Shuqin Xu, Qingjun Huang & Haiyun Xu. (2018) N-acetylcysteine attenuates the cuprizone-induced behavioral changes and oligodendrocyte loss in male C57BL/7 mice via its anti-inflammation actions. Journal of Neuroscience Research 96:5, pages 803-816.
Crossref
Zahra Sepehrmanesh, Mahsa Heidary, Negar Akasheh, Hossein Akbari & Mahshid Heidary. (2018) Therapeutic effect of adjunctive N-acetyl cysteine (NAC) on symptoms of chronic schizophrenia: A double-blind, randomized clinical trial. Progress in Neuro-Psychopharmacology and Biological Psychiatry 82, pages 289-296.
Crossref
Shivangi Patel, Dilip Sharma, Kiran Kalia & Vinod Tiwari. (2017) Crosstalk between endoplasmic reticulum stress and oxidative stress in schizophrenia: The dawn of new therapeutic approaches. Neuroscience & Biobehavioral Reviews 83, pages 589-603.
Crossref
Canan Topcuoglu, Abdurrahim Bakirhan, Fatma Meric Yilmaz, Salim Neselioglu, Ozcan Erel & Safak Yalcin Sahiner. (2017) Thiol/disulfide homeostasis in untreated schizophrenia patients. Psychiatry Research 251, pages 212-216.
Crossref
M. Rapado-Castro, S. Dodd, A. I. Bush, G. S. Malhi, D. R. Skvarc, Z. X. On, M. Berk & O. M. Dean. (2016) Cognitive effects of adjunctive N -acetyl cysteine in psychosis . Psychological Medicine 47:5, pages 866-876.
Crossref
Minori Koga, Anthony V. Serritella, Akira Sawa & Thomas W. Sedlak. (2016) Implications for reactive oxygen species in schizophrenia pathogenesis. Schizophrenia Research 176:1, pages 52-71.
Crossref
Jakub Tomasik, Hassan Rahmoune, Paul C. Guest & Sabine Bahn. (2016) Neuroimmune biomarkers in schizophrenia. Schizophrenia Research 176:1, pages 3-13.
Crossref
P. Steullet, J.H. Cabungcal, A. Monin, D. Dwir, P. O'Donnell, M. Cuenod & K.Q. Do. (2016) Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: A “central hub” in schizophrenia pathophysiology?. Schizophrenia Research 176:1, pages 41-51.
Crossref
Stefania Schiavone & Luigia Trabace. (2016) Pharmacological targeting of redox regulation systems as new therapeutic approach for psychiatric disorders: A literature overview. Pharmacological Research 107, pages 195-204.
Crossref
Joeri Van Liefferinge, Eduard Bentea, Thomas Demuyser, Giulia Albertini, Virginie Follin-Arbelet, Silvia Holmseth, Ellen Merckx, Hideyo Sato, Joeri L. Aerts, Ilse Smolders, Lutgarde Arckens, Niels C. Danbolt & Ann Massie. (2016) Comparative analysis of antibodies to xCT (Slc7a11): Forewarned is forearmed. Journal of Comparative Neurology 524:5, pages 1015-1032.
Crossref
Stefano Marini, Domenico De Berardis, Federica Vellante, Rita Santacroce, Laura Orsolini, Alessandro Valchera, Gabriella Girinelli, Alessandro Carano, Michele Fornaro, Francesco Gambi, Giovanni Martinotti & Massimo Di Giannantonio. (2016) Celecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On Trials. Mediators of Inflammation 2016, pages 1-8.
Crossref
Danielle Stutzman & Julie Dopheide. (2015) Acetylcysteine for treatment of autism spectrum disorder symptoms. American Journal of Health-System Pharmacy 72:22, pages 1956-1959.
Crossref
Becky A. DieboldSusan M.E. SmithYang LiJ. David Lambeth. (2015) NOX2 As a Target for Drug Development: Indications, Possible Complications, and Progress. Antioxidants & Redox Signaling 23:5, pages 375-405.
Crossref
Deepmala, John Slattery, Nihit Kumar, Leanna Delhey, Michael Berk, Olivia Dean, Charles Spielholz & Richard Frye. (2015) Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review. Neuroscience & Biobehavioral Reviews 55, pages 294-321.
Crossref
Kim Q. Do, Michel Cuenod & Takao K. Hensch. (2015) Targeting Oxidative Stress and Aberrant Critical Period Plasticity in the Developmental Trajectory to Schizophrenia. Schizophrenia Bulletin 41:4, pages 835-846.
Crossref
Rebecca Racz, Burgunda V. Sweet & Pamela Sohoni. (2015) Oral acetylcysteine for neuropsychiatric disorders. American Journal of Health-System Pharmacy 72:11, pages 923-929.
Crossref
Irena Smaga, Ewa Niedzielska, Maciej Gawlik, Andrzej Moniczewski, Jan Krzek, Edmund Przegaliński, Joanna Pera & Małgorzata Filip. (2015) Oxidative stress as an etiological factor and a potential treatment target of psychiatric disorders. Part 2. Depression, anxiety, schizophrenia and autism. Pharmacological Reports 67:3, pages 569-580.
Crossref
Georgina Oliver, Olivia Dean, David Camfield, Scott Blair-West, Chee Ng, Michael Berk & Jerome Sarris. (2015) N-Acetyl Cysteine in the Treatment of Obsessive Compulsive and Related Disorders: A Systematic Review. Clinical Psychopharmacology and Neuroscience 13:1, pages 12-24.
Crossref
Michael J. Berridge. (2015) Vitamin D cell signalling in health and disease. Biochemical and Biophysical Research Communications 460:1, pages 53-71.
Crossref
Anilkumar Pillai & Jeffrey K. Yao. 2015. Studies on Psychiatric Disorders. Studies on Psychiatric Disorders 505 520 .
P. O'Donnell, K. Q. Do & C. Arango. (2014) Oxidative/Nitrosative Stress in Psychiatric Disorders: Are We There Yet?. Schizophrenia Bulletin 40:5, pages 960-962.
Crossref
Adam Daniel Zavodnick & Rizwan Ali. (2014) N-Acetylcysteine and Metabotropic Glutamate Receptors: Implications for the Treatment of Schizophrenia: A Literature review. Psychiatric Quarterly 85:2, pages 177-185.
Crossref
Ana P. Herrmann, Radharani Benvenutti, Luísa K. Pilz & Elaine Elisabetsky. (2014) N-acetylcysteine prevents increased amphetamine sensitivity in social isolation-reared mice. Schizophrenia Research 155:1-3, pages 109-111.
Crossref
Chirayu D. Pandya, Kristy R. Howell & Anilkumar Pillai. (2013) Antioxidants as potential therapeutics for neuropsychiatric disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry 46, pages 214-223.
Crossref
Marilena ColaiannaStefania SchiavoneMargherita ZottiPaolo TucciMaria Grazia MorgeseLiselotte BäckdahlRikard HolmdahlKarl-Heinz KrauseVincenzo CuomoLuigia Trabace. (2013) Neuroendocrine Profile in a Rat Model of Psychosocial Stress: Relation to Oxidative Stress. Antioxidants & Redox Signaling 18:12, pages 1385-1399.
Crossref
Michael Berk, Gin S. Malhi, Laura J. Gray & Olivia M. Dean. (2013) The promise of N-acetylcysteine in neuropsychiatry. Trends in Pharmacological Sciences 34:3, pages 167-177.
Crossref
Mehmet Cemal KayaYasin BezIbrahim Fatih KarababaAli EmhanNurten AksoyMahmut BulutMehmet GuneşAbdullah AtliSalih Selek. (2013) Decreased Serum Sulphydryl Levels as a Sign of Increased Oxidative Stress in Generalized Anxiety Disorder. Psychiatry Investigation 10:3, pages 281.
Crossref
C. J. Carter. (2013) Toxoplasmosis and Polygenic Disease Susceptibility Genes: Extensive Toxoplasma gondii Host/Pathogen Interactome Enrichment in Nine Psychiatric or Neurological Disorders . Journal of Pathogens 2013, pages 1-29.
Crossref
Richard Bridges, Victoria Lutgen, Doug Lobner & David A. Baker. (2012) Thinking Outside the Cleft to Understand Synaptic Activity: Contribution of the Cystine-Glutamate Antiporter (System x c − ) to Normal and Pathological Glutamatergic Signaling . Pharmacological Reviews 64:3, pages 780-802.
Crossref
Urs Meyer. (2011) Anti-inflammatory signaling in schizophrenia. Brain, Behavior, and Immunity 25:8, pages 1507-1518.
Crossref
Urs Meyer, Markus J. Schwarz & Norbert Müller. (2011) Inflammatory processes in schizophrenia: A promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. Pharmacology & Therapeutics 132:1, pages 96-110.
Crossref
Ming-Chang Yang & For-Wey Lung. (2011) Neuroprotection of paliperidone on SH-SY5Y cells against β-amyloid peptide25-35, N-methyl-4-phenylpyridinium ion, and hydrogen peroxide-induced cell death. Psychopharmacology 217:3, pages 397-410.
Crossref
Byron K.Y. Bitanihirwe & Tsung-Ung W. Woo. (2011) Oxidative stress in schizophrenia: An integrated approach. Neuroscience & Biobehavioral Reviews 35:3, pages 878-893.
Crossref
Wei-Yi Ong, Kang Sim & Akhlaq A. Farooqui. (2010) Oxidative stress, antioxidant defenses, and schizophrenia. Asia-Pacific Psychiatry 2:4, pages 180-190.
Crossref
Kathryn J. Reissner & Peter W. Kalivas. (2010) Using glutamate homeostasis as a target for treating addictive disorders. Behavioural Pharmacology 21:5-6, pages 514-522.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.